Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a significant growth in short interest in July. As of July 15th, there was short interest totaling 3,033 shares, a growth of 85.7% from the June 30th total of 1,633 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 65,515 shares, the short-interest ratio is currently 0.0 days.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS EMMA opened at $0.01 on Thursday. Emmaus Life Sciences has a 1 year low of $0.01 and a 1 year high of $0.02. The stock’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.01. The firm has a market cap of $701,900.00, a price-to-earnings ratio of -0.08 and a beta of 9.06.

Emmaus Life Sciences (OTCMKTS:EMMA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.05) EPS for the quarter. The company had revenue of $1.98 million during the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.